Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study - Scorecard - MDSpire

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • By

  • Zhong Wang

  • Yimin Zhang

  • Feng Yao

  • Jinxin Li

  • Chenyuan Li

  • Shichong Liao

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Comparison of Trastuzumab Emtansine and Trastuzumab with Pertuzumab in Patients with Residual HER2-Positive Breast Cancer Following Neoadjuvant Therapy: Insights from a Real-World Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsComparison of T-DM1 versus trastuzumab plus pertuzumab in adjuvant treatment, focusing on efficacy and safety.
Target Population
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

    • Adjuvant therapy should start within 12 weeks post-surgery, as per [specific guidelines].
    • T-DM1 recommended for initially unresectable disease or poor pathological response, supported by [specific studies].

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • patient_preferences

        Related Resources & Content

        Original Source(s)

        Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

        • by Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao

        • June 18, 2026

        Related Content

        Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

        Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research

        CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores